Biotech · Private company
Multitude Therapeutics Inc.
Track this companyFree. Adds Multitude Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- AMT-116Phase 3 · NSCLC (Advanced Non-small Cell Lung Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)Phase 3 · NSCLC (Advanced Non-small Cell Lung Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- AMT-116Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyPHASE2_PHASE3 · RECRUITING · started Sep 30, 2026ClinicalTrials.gov NCT07718737 · fetched Nov 12, 2026
- AMT-116 in Patients With Advanced Solid TumorsPHASE1 · RECRUITING · started Jul 25, 2023ClinicalTrials.gov NCT05725291 · fetched Nov 12, 2026